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Abstract
Background: p53 is a tumor suppressor and potent inhibitor of cell growth. P73 is highly similar to p53
at both the amino acid sequence and structural levels. Given their similarities, it is important to determine
whether p53 and p73 function in similar or distinct pathways. There is abundant evidence for negative
cross-talk between glucocorticoid receptor (GR) and p53. Neither physical nor functional interactions
between GR and p73 have been reported. In this study, we examined the ability of p53 and p73 to interact
with and inhibit GR transcriptional activity.
Results: We show that both p53 and p73 can bind GR, and that p53 and p73-mediated transcriptional
activity is inhibited by GR co-expression. Wild-type p53 efficiently inhibited GR transcriptional activity in
cells expressing both proteins. Surprisingly, however, p73 was either unable to efficiently inhibit GR, or
increased GR activity slightly. To examine the basis for this difference, a series of p53:p73 chimeric proteins
were generated in which corresponding regions of either protein have been swapped. Replacing N- and C-
terminal sequences in p53 with the corresponding sequences from p73 prevented it from inhibiting GR. In
contrast, replacing p73 N- and C-terminal sequences with the corresponding sequences from p53 allowed
it to efficiently inhibit GR. Differences in GR inhibition were not related to differences in transcriptional
activity of the p53:p73 chimeras or their ability to bind GR.
Conclusion: Our results indicate that both N- and C-terminal regions of p53 and p73 contribute to their
regulation of GR. The differential ability of p53 and p73 to inhibit GR is due, in part, to differences in their
N-terminal and C-terminal sequences.
Background
The p53 tumor suppressor pathway is inactivated in a
majority of human cancers, either through mutation of
the p53 gene or alterations of p53 regulators or p53-path-
way proteins [1,2]. Wild-type p53 is a transcription factor
that binds the promoter regions of various target genes in
a sequence-specific manner and activates their transcrip-
tion. Some of these target genes are necessary for p53 to
induce cell cycle arrest following stress, such as Waf1,
which encodes the cyclin-dependent kinase inhibitor pro-
tein p21 [3]. Other target genes are important for the
apoptotic function of p53, including Bax,  Fas/Apo1,
PUMA, Noxa, and Apaf1 [4,5]. Cancer-derived mutations
in p53 block its sequence-specific DNA-binding capabil-
ity, resulting in decreased expression of these growth-
inhibitory target genes. This can lead to uncontrolled cell
growth and eventual carcinogenesis.
P73 is a p53-related protein that shares a high degree of
amino acid sequence identity with p53 and many of the
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same structural features [6,7]. Given their similarities, it is
important to determine whether p53 and p73 carry out
similar or distinct functions, and whether they are regu-
lated through similar or different mechanisms. Both p53
and p73 contain an N-terminal transactivation domain
(TAD) and proline-rich domain (PRD), a central DNA-
binding domain (DBD), and a C-terminal oligomeriza-
tion domain (OD) [6,7]. P53 and p73 differ considerably
in their extreme C-terminal sequences. The p53 extreme
C-terminus (residues 364–393) is a basic-charged region
that contains a cluster of six lysine residues. These lysines
are sites of post-translational modifications (acetylation,
ubiquitination, neddylation, methylation) that can regu-
late p53 stability and transcriptional activity [8-12]. In
contrast, p73 contains an extended C-terminus that can
vary in length due to alternative splicing, and that has no
sequence or structural homology with p53. P53 and p73
can carry out some redundant functions. For example,
p73 can bind to and activate various p53 target genes, and
can induce growth arrest or apoptosis when over-
expressed [13,14]. Further, levels of endogenous p73 pro-
tein increase in response to certain stresses, as does p53,
and this p73 can induce apoptosis in p53-null cells
[15,16]. Despite these similarities, however, the conse-
quence of p53 or p73 loss on development and cancer
susceptibility is strikingly different. P53 loss-of-function
mutations are found in over 50% or all human cancers,
and p53-deficient mice develop multiple cancers and die
at an early age [17-19]. This is consistent with p53s role as
a bona fide tumor suppressor. In contrast, mutations in
p73 are not commonly associated with cancer, and p73-
deficient mice display neurological, pheromonal, and
inflammatory defects without an apparent increased can-
cer incidence [20]. These findings and others have sug-
gested that p73 could play distinct roles in development
that are not attributed to p53.
Glucocorticoid receptor (GR) is a nuclear receptor and lig-
and-dependent transcription factor (reviewed in [21,22]).
GR belongs to the superfamily of steroid nuclear receptors
that also includes estrogen receptor (ER), androgen recep-
tor (AR), and progesterone receptor (PR). In the absence
of ligand, GR is inactive and resides in the cytoplasm in
complex with chaperones such as Hsp90. Ligand-binding
promotes dissociation of GR from cytoplasmic complexes
and its translocation to the nucleus, where it can then acti-
vate transcription of its target genes. The effect of activat-
ing GR appears to be cell-type specific. GR activation has
been reported to promote survival and inhibit apoptosis
in mammary epithelial cells, breast cancer cells, neurob-
lastoma cells, and other cell types [23-28]. In contrast, GR
activation in thymocytes triggers apoptosis (reviewed in
[29]). There is compelling evidence for cross-talk between
GR and p53. Binding between GR and p53 has been dem-
onstrated both in vitro and in vivo, and their interaction
can lead to the mutual inhibition of both proteins
[27,28]. The GR ligand dexamethasone has been reported
to enhance binding between GR and p53 and, under cer-
tain conditions, to cause their cytoplasmic sequestration
and degradation [28]. Complexes of p53 and GR may also
contain MDM2, a p53-responsive protein that can act as
an E3 ubiquitin ligase to promote degradation of both
p53 and GR [28]. These findings have suggested that GR
could enhance survival by sequestering p53 in the cyto-
plasm and, conversely, that p53 might enhance cell death
by sequestering GR in the cytoplasm and blocking its sur-
vival function. To date, neither physical nor functional
interactions between GR and p73 have been described.
In the current study, we examined whether p73 could
bind GR and participate in negative cross-talk with GR,
similar to p53. We found that both p53 and p73 could
bind GR, and that p53 and p73-mediated transcriptional
activity was inhibited by GR co-expression. Wild-type p53
efficiently inhibited GR transcriptional activity in cells
expressing both proteins. Surprisingly, however, p73 was
either unable to effectively inhibit GR, or increased GR
activity slightly. To examine the basis for this difference,
we generated a series of p53:p73 chimeric proteins in
which corresponding regions of either protein have been
swapped. These studies revealed that N- and C-terminal
regions of p53 and p73 contribute to their regulation of
GR. Fusion of p53 N- and C-terminal sequences to p73
allowed p73 to inhibit GR and, conversely, fusion of p73
N- and C-terminal sequences to p53 prevented p53 from
inhibiting GR. We conclude that the differential ability of
p53 and p73 to inhibit GR is due, in part, to differences in
their N-terminal and C-terminal sequences.
Results
Both p53 and p73 can bind GR
P53, p73, and GR are each short-lived proteins that
undergo proteasome-dependent degradation [30-32]. GR
is targeted for proteasomal degradation in the presence of
its activating ligand dexamethassone (Dex) [28]. P53 can
bind GR and has also been reported to undergo enhanced
degradation upon Dex-treatment [28]. We wished to test
whether p73 can also bind GR. First, Saos-2 cells (p53-
null) were transfected with DNAs encoding either GR only
(Fig. 1A), or co-transfected with GR and p53 or p73β (Fig.
1B). Cells were then either untreated or treated with Dex
for 17 hrs, followed by incubation for an additional 6 hrs
in the presence or absence of the proteasome inhibitor
MG132. GR levels decreased with Dex treatment when
expressed alone or with p53 or p73β, and this decrease
was partially blocked by MG132. P53 and p73 levels were
similarly decreased in Dex treated cells, and this decrease
was also partially blocked by MG132-treatment (Figs 1A
and 1B). The results suggest Dex treatment may enhance
proteasomal degradation of p53, p73, and GR under these
conditions.
We next asked whether binding between GR and either
p53 or p73 could be detected. For this, Saos-2 cells wereMolecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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Glucocorticoid receptor (GR) binding to p53 and p73 Figure 1
Glucocorticoid receptor (GR) binding to p53 and p73. A and B, Saos-2 cells (p53-null) were transfected overnight with 
200 ng GR DNA and 100 ng DNA encoding either p53 or p73β. Where indicated, transfected cells were treated with dexam-
ethasone (Dex, 100 nM) for 17 hrs and then incubated in the presence or absence of MG132 (30 µM) for an additional 6 hrs. 
GR, p53, and p73 levels were monitored by immunblotting. C, Saos-2 cells were transfected with DNAs encoding GR, HA-p53, 
or HA-p73β (1 µg each) as indicated. Transfected cells were either untreated (no tr), treated with dexamethasone (+Dex, 100 
nM) for 24 hrs, treated with MG132 (30 µM) for 6 hrs, or treated with dexamethasone for 17 hrs followed by incubation in 
dexamethasone plus MG132 for an additional 6 hrs. Cell lysates were immunoprecipitated with GR polyclonal antibody, fol-
lowed by immunoblotting with a HA monoclonal antibody. The position of HA-p53 (left) and HA-p73β (right) that co-immuno-
precipitated with GR is indicated. The asterisk indicates detection of the antibody heavy chain used in the immunoprecipitation. 
Levels of GR, HA-p53, and HA-p73 in transfected cell lysates determined by immunoblotting without prior immunoprecipita-
tion are shown in the lower panels.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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transfected with expression DNAs (1 µg each) encoding
GR and HA-tagged p53 or p73β. Transfected cells were
then either untreated or treated with Dex for 17 hrs, fol-
lowed by incubation for an additional 6 hrs in the pres-
ence or absence of MG132 to block their potential
degradation. Cell lysates were immunoprecipitated with a
GR antibody, followed by immuno-blotting with an HA
antibody to detect co-immunoprecipitating p53 or p73β.
As shown in Fig. 1C, both p53 and p73β co-immunopre-
cipitated with GR. Interestingly, binding between trans-
fected GR and p53 or p73β was most evident in cells
treated with MG132, suggesting the ability to detect GR
complexes with p53 or p73 may be limited by their pro-
teasomal degradation. p53 appeared to bind GR to a
slightly greater extent than did p73β.
GR inhibits p53 and p73 transcriptional activity
Given that GR can bind p53 and p73, we wished to test
whether GR could inhibit p53 or p73 transcriptional
activity. To this end, Saos-2 cells were transfected with dif-
ferent p53 and p73-responsive luciferase reporter genes
(pG13-luc, MDM2-luc, and p21-luc) either alone, or with
p53, p73 and GR in different combinations. p53 or p73-
dependent transactivation of these reporter genes was
assessed. As shown in Figs. 2A and 2B, p53 and p73 acti-
vated expression of each reporter gene. Co-expression of
GR without Dex treatment, or treatment with Dex alone,
had little or no effect on this p53 or p73-dependent acti-
vation. However, p53 and p73 activity was inhibited in
each case when cells co-expressing GR were also treated
with Dex. This indicates that GR, in the presence of its lig-
and (Dex), can inhibit the transcriptional activity of both
p53 and p73.
P53, but not p73, can efficiently inhibit GR transcriptional 
activity
P53 has been reported to inhibit the transcriptional activ-
ity of GR [28,33]. To test whether p73 can also inhibit GR
activity, we monitored activation of a GR-responsive luci-
ferase reporter gene (GR-luc, Fig. 3) when GR was co-
expressed with p53 or p73. GR-luc was not activated by
GR expression alone (Fig. 3A) or by Dex treatment alone.
However, as shown in Fig. 3A, GR-luc was highly activated
when cells transfected with GR expression DNA were
treated with Dex. Expression of p53 at increasing amounts
inhibited the transcriptional activity of GR (Figs. 3A and
3B), consistent with previous results. In contrast, and sur-
prisingly, co-expression with increasing amounts of p73
inhibited GR either less efficiently than p53 or not at all,
and low levels of transfected p73 actually increased GR
activity (Figs. 3A and 3B). Thus, p53 and p73 differ in
their abilities to inhibit GR transcriptional activity.
P73 fails to inhibit GR when MDM2 is over-expressed
Wasylyk and colleagues reported that p53 may inhibit GR
through activation of MDM2 [28]. According to this
model, p53 activates MDM2 gene expression, and
increased levels of MDM2 protein then promotes GR and
p53 degradation. We observed lower induction of MDM2
in cells expressing p73 compared to cells expressing p53
(Figs. 3A and 3B), suggesting that the relative inability of
p73 to inhibit GR might be due to its less efficient induc-
tion of MDM2. To test this possibility, we first monitored
p53 inhibition of GR under conditions where endog-
enous MDM2 expression was inhibited by siRNA (Fig.
4A). The results show that p53 could still inhibit GR
under conditions where MDM2 levels were decreased by
siRNA, though knockdown of MDM2 diminished p53
inhibition of GR slightly. This suggested MDM2 may con-
tribute to GR inhibition by p53, but is not absolutely
required. Next, we monitored GR inhibition by p53 and
p73 in MDM2/p53 double knockout (DKO) cells. p53
efficiently inhibited GR activity in these p53/MDM2 DKO
cells, whereas p73 did not (Fig. 4B). Thus, the different
ability of p53 and p73 to inhibit GR is observed even in
the absence of MDM2 expression. Finally, we asked
whether artificially increasing MDM2 levels would allow
p73 to inhibit GR activity. To this end, GR activity was
monitored in cells expressing increasing amounts of p73
either alone, or with increasing amounts of MDM2 (Fig.
4C). p73 was unable to inhibit GR activity when expressed
alone or with MDM2, and MDM2 alone also had no effect
on GR activity. Based on these results it appears that the
differential ability of p53 and p73 to inhibit GR activity
does not result from lesser induction of MDM2 by p73.
Chimeric p53:p73 proteins have altered abilities to inhibit 
GR
P53 and p73 share considerable amino acid sequence and
structural similarity. We considered that one or more
unique sequence elements in p53 or p73 might account
for their different abilities to inhibit GR. To explore this
possibility, a series of p53:p73 chimeric proteins were
generated in which corresponding regions of either pro-
tein have been swapped (Figs. 5A and 8A). The high
degree of structural homology between p53 and p73
should allow one to switch the various domains of each
protein without disrupting protein conformation. A simi-
lar approach was used by Yuan et al. to identify specific
sequence elements in p53 that confer degradation by
MDM2 [34]. Deletion mutants of p53 and p73 were also
generated that lack the conserved N-terminus of each pro-
tein (p53 ∆1–42 and p73 ∆1–54) or the unique C-termi-
nus of each protein [p53 (1–363) and p73 (1–390)] (Fig.
5A). Transcriptional activity of each clone was tested by
monitoring activation of the p53 reporter gene pG13-luc
in transfected cells (Figs. 5B and 8B). p53 (1–363) had
increased transcriptional activity compared to wild-typeMolecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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GR inhibits p53 and p73 transcriptional activity Figure 2
GR inhibits p53 and p73 transcriptional activity. A, Saos-2 cells were transfected with DNAs encoding p53 (50 ng), the 
indicated p53/p73-responsive reporter DNA (pG13-luc, p21-luc, or MDM2-luc, 100 ng each), and GR (100, 250, 500 ng for 
pG13-luc; 500 ng for p21-luc and MDM2-luc). 24 hrs after transfection, cells were untreated or treated with dexamethasone 
(100 nM) for an additional 20 hrs. Luciferase activity in transfected cell lysates was determined. The fold change in pG13-luc 
activity is plotted (+/- standard error of the mean, s.e.m.) from multiple experiments compared to the activity of pG13-luc 
alone, whose value is considered 1.0. Relative luciferase activity (RLU) is plotted (+/- s.e.m.) for MDM2-luc and p21 luc. Repre-
sentative immunoblots for each experiment are shown. B, Same as in A above, but with transfection of p73β DNA (50 ng).Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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p53 (compare clones 1 and 5, Fig. 5B), consistent with
early and more recent reports that the p53 C-terminus
harbors a transcription inhibitory domain [35,36]. In
contrast, p73 (1–390) had lower transcriptional activity
compared to wild-type p73β, consistent with reports that
the p73 C-terminus harbors a transcriptional activation
domain (TAD) [37]. Similarly, p53 with the p73 C-termi-
nus (clone 9, Figs. 5A and 5B) had high transcriptional
activity, consistent with the transcription inhibitory
domain of p53 being replaced with the C-terminal tran-
scriptional activation of p73. Finally, p73 with the p53 C-
terminus (clone 10, Figs. 5A and 5B) had very low activity,
consistent with replacement of its C-terminal transcrip-
tional activation domain with the transcription inhibitory
domain of p53. As expected, p53 and p73 that lacked N-
terminal sequences (p53 ∆1–42 and p73 ∆1–54) lacked
transcriptional activity due to deletion of their N-terminal
TAD.
To examine the role that p53/p73 C-terminal sequences
may play in GR inhibition, we monitored GR activity
when co-expressed with the C-terminal deletion mutants
p53 and p73 differ in their ability to inhibit GR transcriptional activity Figure 3
p53 and p73 differ in their ability to inhibit GR transcriptional activity. A, Saos-2 cells were transfected with the GR-
responsive luciferase reporter GR-luc (200 ng), and DNA encoding GR (100 ng), and increasing amounts of HA p53 or HA 
p73β DNA (250, 500, 1000 ng) as indicated. 24 hrs after transfection, cells were untreated or treated with dexamethasone 
(100 nM) for an additional 20 hrs. Luciferase activity in transfected cell lysates was determined and relative luciferase activity 
(RLU) is plotted from triplicate experiments (+/- s.e.m.). Lower Representative immunoblot shows p53, p73, GR, and MDM2 
expression levels in this experiment. B, Saos-2 cells were transfected with the GR responsive reporter GR-luc (200 ng) and 
DNA encoding GR (100 ng), and increasing amounts of Flag p53 or Flag p73β DNA (50, 100, 250, 500, 750, 1000 ng) as indi-
cated. 24 hrs after transfection, cells were untreated or treated with dexamethasone (100 nM) for an additional 20 hrs. Luci-
ferase activity in transfected cell lysates was determined and are plotted. The fold change in GR-luc activity is plotted (+/- 
s.e.m.) from multiple experiments compared to the activity of GR-luc alone, whose value is considered 1.0. Lower, Representa-
tive immunoblot shows GR, p53, p73, and MDM2 protein levels in transfected cell lysates.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
Page 7 of 18
(page number not for citation purposes)
of p53 and p73. As shown in Fig. 6B, p53 (1–363) inhib-
ited GR equally well as p53 wt. Interestingly, p73 (1–390)
did not increase GR activity as p73 wt did, and gained
some ability to inhibit GR compared to p73 wt, especially
at high input amounts. When equal protein expression
levels were compared (as determined by densitometric
scanning of films), p73 (1–390) had a slightly lesser abil-
ity to inhibit GR than p53 (1–363). These results indicate
that 1) p53 C-terminal sequences are not absolutely
required to inhibit GR, and 2) that p73 C-terminal
sequences may contribute to GR activation by p73, and
may limit p73s ability to inhibit GR. Next, we examined
GR inhibition by the p53:p73 chimeric proteins in which
the C-terminal sequences (C-term) have been swapped
(Fig. 6B). p53 with the p73 C-term [p53(73βaa391–499)]
was still able to inhibit GR activity (Fig. 6B). In contrast,
p73 with the p53 C-term [p73β(53aa363–393)] had a
slightly greater inhibitory effect on GR when compared
with p73 (1–390). Based on these results it appears that
differences in the unique C-terminal sequences of p53
and p73 may only partially explain their different abilities
to inhibit GR. It is important to note there is not a strict
relationship between the transcriptional activity of p53 or
p73 and their ability to inhibit GR. For example, p53 (1–
363) had increased transcriptional activity compared to
p53 wt, but did not display increased ability to inhibit GR,
while p73 (1–390) had decreased transcriptional activity
compared to p73 wt but inhibited GR to a slightly greater
extent. Similarly, p53 with the p73 C-terminus had the
highest transcriptional activity but inhibited GR equally
Role of MDM2 in GR inhibition by p53 and p73 Figure 4
Role of MDM2 in GR inhibition by p53 and p73. A, Saos-2 cells were transfected with GR-luc DNA (200 ng) and increas-
ing amounts of DNA encoding p53 (100, 250, 500, 750 ng). Where indicated cells were also transfected with DNA encoding 
siRNA directed against MDM2 (si MDM2). 24 hrs after transfection, cells were treated with dexamethasone (100 nM) for an 
additional 20 hrs, and luciferase activity in transfected cell lysates determined. Fold change in GR-luc activity is plotted (+/- 
s.e.m.) from multiple experiments compared to the activity of GR-luc alone, whose value is considered 1.0. GR, MDM2, and 
p53 immunoblots are shown below. B, MDM2/p53 double knockout (DKO) cells were transfected with GR-luc DNA (200 ng) 
and increasing amounts of DNA encoding p53 or p73 (50,100, 250, 500, 750, 1000 ng). Cells were treated with dexametha-
sone (100 nM) as described above, and luciferase activity in transfected cell lysates determined. Fold change in GR-luc activity 
is plotted compared to the activity of GR-luc alone, whose value is considered 1.0. Representative GR, p53 and p73 immunob-
lots are shown below. C, Saos-2 cells were transfected with GR-luc DNA (200 ng) and increasing amounts DNA encoding p73 
(250, 500, 1000 ng). Where indicated cells were also transfected with the indicated amount DNA encoding MDM2 (250, 500, 
1000 ng). Cells were treated with dexamethasone (100 nM) as described above and luciferase activity determined. Fold change 
in GR-luc activity is plotted. Representative GR, MDM2, and p73 immunoblots are shown below.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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p53 and p73 chimeric proteins Figure 5
p53 and p73 chimeric proteins. A, Schematic of the Flag-tagged p53 and p73 wild-type (wt) and chimeric proteins. TAD = 
N-terminal transactivation domain, PRD = proline-rich domain, DBD = DNA-binding domain,, oligo = oligomerization domain, 
C-term = C-terminal domain. In this diagram, clear (unfilled) areas are from p53, and gray (filled) areas are from p73β. Num-
bers indicate the amino acid sequence positions in each protein. B, Saos-2 cells were co-transfected with 100 ng pG13-luc 
DNA and 50 or 100 ng DNA encoding the indicated protein from A. The fold change in pG13-luc activity is plotted compared 
to the activity of pG13-luc alone, whose value is considered 1.0. Results are the average from two experiments.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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or slightly less well than p53 wt, while p73 with the p53
C-terminus had very little activity but inhibited GR to a
greater extent than p73 wt.
To examine the role that p53/p73 N-terminal sequences
may play in GR inhibition, we first monitored GR activity
when co-expressed with N-terminal deletion mutants of
p53 or p73. As shown in Fig. 7B, p53 ∆1–42 was unable
to inhibit GR at all input amounts. p73 ∆1–54 was also
unable to inhibit GR and, interestingly, also did not
increase GR activity at low input amounts as p73 wt did.
These results indicate that 1) p53 N-terminal sequences
included within the N-terminal TAD are required for p53
to inhibit GR, and 2) that p73 N-terminal sequences may
contribute to the slight activation of GR that is observed
with p73 wt expression. Next, we examined GR inhibition
by the p53:p73 chimeric proteins in which their N-termi-
nal TAD sequences have been swapped (Fig. 7B). p53 with
the p73 TAD [p53(73βaa1–54)] was still able to inhibit
GR activity, though somewhat less well than p53 wt at low
input amounts (Fig. 7B). In contrast, p73 with the p53
TAD [p73β(53aa1–45)] gained some ability to inhibit
GR, especially at high input amounts. When equal protein
expression levels were compared (as determined by densi-
tometric scanning), p73β(53aa1–45) was slightly less
able to inhibit GR than p53(73βaa1–54). Based on this it
seems the different abilities of p53 and p73 to inhibit GR
may also be explained partially, but not fully, by differ-
ences in their N-terminal TAD sequences.
To explore the differences between p53 and p73 further, a
second set of p53:p73 chimeric proteins were generated in
which larger regions of the N- and C-terminus of each pro-
tein were swapped (Fig. 8A). Chimeric proteins were also
generated in which large N-terminal and C-terminal
regions of p53 and p73 were swapped simultaneously
(clones 15 and 16, Fig. 8A). These chimeric clones dis-
played varying levels of transcriptional activity, as moni-
tored by activation of the pG13-luc reporter (Fig. 8B). We
first examined GR inhibition by the p53:p73 chimeric
proteins in which both the oligo and C-terminal (C-term)
sequences have been swapped (Fig. 9B). p53 with the p73
oligo and C-term [p53(73βaa328–499)] was still able to
inhibit GR activity, though with a slightly lesser ability
than p53 wt at low input amounts. p73 with the p53 oligo
and C-terminal domain [p73β(53aa290–393)] could also
inhibit GR. When equal protein expression levels were
compared (as determined by densitometric scanning of
C-terminal sequences in p53 and p73 affect their ability to inhibit GR Figure 6
C-terminal sequences in p53 and p73 affect their ability to inhibit GR. A, Schematic of p53 and p73 C-terminal dele-
tion mutants (∆C) and C-term swap mutants. B, Saos-2 cells were transfected with the GR-responsive luciferase reporter GR-
luc (200 ng), GR DNA (100 ng), and increasing amounts DNA encoding the indicated p53:p73 protein (50 – 1000 ng of each 
DNA). Transfected cells were treated with Dex (100 nM) as described earlier, and luciferase activity in transfected cell lysates 
was determined. Fold change in GR-luc activity is plotted (+/- s.e.m.) from multiple experiments compared to the activity of 
GR-luc alone, whose value is considered 1.0. C, Representative immunoblots show the level of each protein.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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films), [p73β(53aa290–393)] and [p53(73βaa328–499)]
inhibited GR with comparable efficiencies. These results
are consistent with those of Fig. 6 and indicate the differ-
ent abilities of p53 and p73 to inhibit GR may be
explained in part, but not fully, by differences in their C-
terminal sequences, including the oligo and C-term
domains. Next, we examined GR inhibition by the
p53:p73 chimeric proteins in which both the N-terminal
TAD and proline rich domain (PRD) have been swapped
(Fig. 10B). p53 with the p73 TAD and PRD [p53(73βaa1–
113)] was still able to inhibit GR activity, though less well
than p53 wt or p53 with only the p73 TAD swapped
(compare GR inhibition in Fig. 7C and Fig. 9B). In con-
trast, p73 with the p53 TAD and PRD [p73β(53aa1–97)]
gained ability to inhibit GR. When equal protein expres-
sion levels were compared, [p73β(53aa1–97)] appeared
to inhibit GR to a greater extent than [p53(73βaa1–113)].
These results indicate the different abilities of p53 and
p73 to inhibit GR may be explained in part, but not fully,
by differences in their N-terminal sequences, including
the TAD and PRD domains. Finally, we examined GR
inhibition by p53:p73 chimeric proteins in which both N-
terminal and C-terminal sequences have been swapped
simultaneously (Fig. 11B). Strikingly, p53 with both the
p73 N-terminus and C-terminus [p53(73βaa1–113+328–
499)] was completely unable to inhibit GR activity and,
like p73 wt, activated GR slightly at lower input amounts.
In contrast, p73 with both the p53 N-terminus and C-ter-
minus [p73β(53aa1–97+290–393)] efficiently inhibited
GR at all input amounts, and to an extent similar to p53
wt. It is important to note that both these clones displayed
comparable levels of transcriptional activity (clones 15
and 16, Fig. 8B). Further, co-immunoprecipitation exper-
iments demonstrated that both chimeric proteins could
bind GR to equal extents (Fig. 11D), indicating their dif-
ferent abilities to inhibit GR did not result from differ-
ences in GR binding. We conclude that the different
ability of p53 and p73 to inhibit GR results from differ-
ences in their N-terminal and C-terminal sequences, and
is not due to differences in their transcriptional activity or
GR-binding.
Discussion
Binding between p53 and GR has been demonstrated in
vivo and in vitro, and p53 and GR can inhibit each others
transcriptional activity in transfected cells [27,28]. Moreo-
ver, activation of endogenous GR by Dex treatment inhib-
ited p53 induced cell cycle arrest in stressed cells, and
activation of endogenous p53 by DNA damage inhibited
GR transcriptional activity [27,28]. These findings and
N-terminal sequences in p53 and p73 affect their ability to inhibit GR Figure 7
N-terminal sequences in p53 and p73 affect their ability to inhibit GR. A, Schematic of p53 and p73 N-terminal dele-
tion mutants (∆N) and N-terminal TAD swap mutants. B, Saos-2 cells were transfected with the GR-responsive luciferase 
reporter GR-luc (200 ng), GR DNA (100 ng), and increasing amounts DNA encoding the indicated p53:p73 protein (50 – 1000 
ng of each DNA). Transfected cells were treated with Dex (100 nM) as described earlier, and luciferase activity in transfected 
cell lysates was determined. Fold change in GR-luc activity is plotted (+/- s.e.m.) from multiple experiments compared to the 
activity of GR-luc alone, whose value is considered 1.0. C, Representative immunoblots show the level of each protein.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
Page 11 of 18
(page number not for citation purposes)
p53 and p73 chimeric proteins with larger N- and C-terminal swaps Figure 8
p53 and p73 chimeric proteins with larger N- and C-terminal swaps. A, Schematic of the p53 and p73 chimeric pro-
teins in which larger portions of the N- and C-terminus have been swapped. B, Saos-2 cells were co-transfected with 100 ng 
pG13-luc DNA and 50 or 100 ng DNA encoding the indicated protein from A. The fold change in pG13-luc activity is plotted 
compared to the activity of pG13-luc alone, whose value is considered 1.0. Results are the average from two experiments.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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C-terminal sequences affect p53 and p73 inhibition of GR Figure 9
C-terminal sequences affect p53 and p73 inhibition of GR. A, Schematic of p53 and p73 C-terminal swap mutants in 
which the oligo and C-term have been swapped. B, Saos-2 cells were transfected with the GR-responsive luciferase reporter 
GR-luc (200 ng), GR DNA (100 ng), and increasing amounts DNA encoding wt p53 or p73, or the indicated p53:p73 C-termi-
nal swap mutants (50 – 1000 ng of each DNA). Transfected cells were treated with Dex (100 nM) as described earlier, and 
luciferase activity in transfected cell lysates determined. Fold change in GR-luc activity is plotted (+/- s.e.m.) from multiple 
experiments compared to the activity of GR-luc alone, whose value is considered 1.0. C, Representative immunoblots show the 
level of each protein.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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N-terminal sequences affect p53 and p73 inhibition of GR Figure 10
N-terminal sequences affect p53 and p73 inhibition of GR. A, Schematic of p53 and p73 N-terminal swap mutants in 
which the N-terminal TAD and PRD have been swapped. B, Saos-2 cells were transfected with the GR-responsive luciferase 
reporter GR-luc (200 ng), GR DNA (100 ng), and increasing amounts DNA encoding the indicated p53:p73 protein (50 – 1000 
ng of each DNA). Transfected cells were treated with Dex (100 nM) as described earlier, and luciferase activity in transfected 
cell lysates was determined. Fold change in GR-luc activity is plotted (+/- s.e.m.) from multiple experiments compared to the 
activity of GR-luc alone, whose value is considered 1.0. C, Representative immunoblots show the level of each protein.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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N-terminal and C-terminal sequences in p53 allow inhibition of GR Figure 11
N-terminal and C-terminal sequences in p53 allow inhibition of GR. A, Schematic of p53 and p73 swap mutants in 
which N-terminal and C-terminal sequences have been swapped simultaneously. B, Saos-2 cells were transfected with the GR-
responsive luciferase reporter GR-luc (200 ng), GR DNA (100 ng), and increasing amounts DNA encoding the indicated 
p53:p73 protein (50 – 1000 ng of each DNA). Transfected cells were treated with Dex (100 nM) as described earlier, and luci-
ferase activity in transfected cell lysates was determined. Fold change in GR-luc activity is plotted (+/- s.e.m.) from multiple 
experiments compared to the activity of GR-luc alone, whose value is considered 1.0. C, Representative immunoblots show the 
level of each protein. D, (Left) Lysates from Saos-2 cells transiently expressing GR and the indicated p53/p73 swap mutants 
were immunoprecipitated with a GR antibody and examined by immunoblotting with an anti-Flag antibody (GR IP/Flag IB). 
Arrowheads indicate the position of the indicated p53/p73 swap mutant. The asterisk indicates the position of the antibody 
heavy chain used in the immunoprecipitation. (Right) Lysates were examined prior to immunoprecipitation to show the rela-
tive input amounts of each protein.Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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others support the existence of negative cross-talk
between the p53 and GR pathways. The GR-binding site
in p53 has been mapped to the p53 DNA-binding domain
(DBD) [28], and Dex treatement was reported to both
enhance p53-GR binding and promote their proteasomal
degradation to some extent. P53 and p73 are structurally
similar and share high amino acid sequence identity in
their DBD and other domains. However, to date, neither
physical nor functional interactions between p73 and GR
have been reported. In some but not all experiments, GR
and p53 levels decreased upon Dex treatment in cells co-
expressing both proteins, and this was partially blocked
by proteasome inhibition. GR and p73 levels were also
decreased in Dex-treated cells in some experiments (Fig.
1B). This suggests Dex treatment may promote proteaso-
mal degradation of GR, p53, and p73. Our co-immuno-
precipitation studies (Fig. 1C) indicate that p73 can also
bind GR, similar to p53. Interestingly, binding between
GR and p53 or p73β was most evident in cells treated with
the proteasome inhibitor MG132. This suggests the ability
to detect GR complexes with p53 or p73 may be limited
by their proteasomal degradation. Alternatively, MG132
may stabilize one or more factors that enhance the inter-
action between GR and either p53 or p73.
GR can inhibit the transcriptional activity of p53. To test
whether GR can also inhibit the transcriptional activity of
p73, we monitored the effect of GR co-expression on p53
and p73-dependent activation of different luciferase
reporter genes. GR inhibited transactivation of all three
reporter genes by p53 or p73 to comparable extents. Thus,
p53 and p73 can bind GR, and the transcriptional activity
of both proteins is inhibited by GR. We also monitored
the effect of p53 or p73 co-expression on the transcrip-
tional activity of GR. In all experiments, p53 caused a pro-
nounced inhibition of GR activity. Surprisingly, however,
p73 was either unable to efficiently inhibit GR, or acti-
vated GR slightly (Fig. 3). Thus, p53 and p73 can bind GR,
but only p53 and not p73 can efficiently inhibit GR activ-
ity. One interesting possibility based on these results is
that the mechanism by which GR inhibits p53 and p73
may be different from the mechanism by which p53 or
p73 inhibits GR. Binding to p53 or p73 may be sufficient
for GR to inhibit p53 and p73 activity. However, binding
alone may not be sufficient for p53 or p73 to inhibit GR,
since p73 can bind GR just as p53 can, but is unable to
efficiently inhibit GR activity.
Wasylyk and colleagues reported one way in which p53
can inhibit GR is through its activation of MDM2 [28].
According to this model, p53 activates MDM2 gene
expression, and increased levels of MDM2 protein then
promote the degradation of both p53 and GR. We
observed that p53 could still efficiently inhibit GR activity
either when endogenous MDM2 levels were decreased via
siRNA, or in MDM2/p53 double-knockout cells. While
MDM2 may contribute to GR inhibition by p53, our
results indicate p53 can also inhibit GR through an
MDM2-independent mechanism. P73 induced lower lev-
els of MDM2 than did p53. However, p73 remained una-
ble to inhibit GR activity when expressed with increasing
amounts of MDM2, and MDM2 alone also had no effect
on GR activity. These results indicate the different abilities
of p53 and p73 to inhibit GR results from something
other than differences in MDM2 levels.
We considered two possibilities might explain the differ-
ent abilities of p53 and p73 to inhibit GR. First, p53 may
contain one or more unique sequence elements that are
absent from p73, and that allow p53 to inhibit GR. Sec-
ond, p73 may contain one or more unique sequence ele-
ments that are missing from p53, and that prevent p73
from inhibiting GR. To investigate these possibilities, a
series of p53:p73 chimeric proteins were generated in
which corresponding regions of either protein have been
swapped (Figs. 5A and 8A). The high degree of structural
homology between p53 and p73 should allow one to
switch the various domains of each protein without dis-
rupting protein conformation. This approach was used
previously by Yuan and colleagues to identify specific
sequence elements in p53 that confer its degradation by
MDM2 [34]. Our studies revealed that replacing C-termi-
nal domains (oligo and C-term) in p53 with the corre-
sponding domains of p73 had little effect, or only slightly
diminished, the ability of p53 to inhibit GR. Conversely,
deleting the unique C-terminus of p73, or replacing C-ter-
minal domains (oligo and C-term) in p73 with the corre-
sponding domains of p53 allowed p73 to inhibit GR to a
large extent. Replacing the N-terminal domains (TAD and
PRD) in p53 with the corresponding domains of p73
diminished the ability of p53 to inhibit GR, whereas
replacing the N-terminal domains in p73 with the corre-
sponding domains of p53 allowed p73 to inhibit GR to
some extent. These results suggested that the different
abilities of p53 and p73 to inhibit GR can be explained in
part, but not fully, by individual differences in their N-
and C-terminal sequences. Confirmation of this came
from analysis of p53:p73 chimeric proteins in which their
N- and C-terminal sequences were swapped simultane-
ously (Fig. 11). Replacement of p53s N- and C-terminal
sequences with the N- and C-terminal sequences of p73 at
the same time completely blocked its ability to inhibit GR,
while replacement of p73s N- and C-terminal sequences
with the N- and C-terminal sequences of p53 at the same
time allowed it to efficiently inhibit GR. Importantly, the
different ability of these chimeric proteins to inhibit GR
was not due to differences in their transcriptional activity
or ability to bind GR. The results suggest that p53 N- and
C-terminal sequences contribute to its inhibition of GR,
since these sequences cannot be replaced by the corre-Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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sponding sequences of p73. In contrast, p73 N- and C-ter-
minal sequences appear to prevent GR inhibition, since
deletion of C-terminal sequences from p73 restored some
ability to inhibit GR, and replacing p53s N- and C-termi-
nal sequences with those of p73 blocked p53 from inhib-
iting GR. This raises the question of how the N- and C-
terminal sequences of p53 or p73 might participate in GR
inhibition. A recent study suggested that p53 could
repress transcription of the IGFBP-1 gene through recruit-
ment of a histone deacetylase (HDACs) [38]. Interest-
ingly, this recruitment of HDAC required both N-terminal
and C-terminal sequences in p53. Perhaps p53 can bind
GR on promoter DNA and repress its activity through N-
and C-terminal sequences and HDAC recruitment. p73
might lack the ability to recruit HDAC protein(s) or only
recruit HDACs inefficiently, accounting for its inability to
inhibit GR.
Conclusion
p53 and p73 transcriptional activity is inhibited by gluco-
corticoid receptor (GR) co-expression. However, whereas
wild-type p53 efficiently inhibits GR transcriptional activ-
ity, p73 is either unable to efficiently inhibit GR, or
increases GR activity slightly. These differences are not due
to differences in the ability of p53 and p73 to either bind
GR, or activate MDM2 gene expression. Analysis of multi-
ple p53:p73 chimeric proteins revealed that the differen-
tial ability of p53 and p73 to inhibit GR is due to
differences in their N-terminal and C-terminal sequences.
Methods
Plasmid DNAs
HA-tagged and Flag-tagged p53 wt DNAs were described
previously [39]. HA-tagged human p73β DNA was from
Frank Mckeon (Harvard Medical School). Flag-tagged
p73β was generated by PCR amplifying p73β sequences
from HA p73β DNA and cloning them into Bam HI and
Xba I sites downstream of the Flag epitope. p53(73βaa1–
54), and p73β(53aa1–45) DNAs were gifts from Zhimin
Yuan (Harvard School of Public Health. All other DNAs
encoding human p53:p73β chimeric proteins were gener-
ated by two-step PCR method, as described previously
[34]. All chimeric DNAs were confirmed by DNA sequenc-
ing. Oligonucleotide sequences used in cloning are avail-
able on request. DNA encoding glucocorticoid receptor
(GR) and GR-responsive luciferase reporter gene (GR-luc)
was from E.A. Thompson (University of Texas Medical
Branch, Galveston, TX). GR-luc contains two copies of a
GR-responsive element from the rat angiotensin gene
upstream of minimal promoter. PG13-luc DNA was from
Bert Vogelstein (Johns Hopkins). P21-luc and MDM2-luc
DNA were from Moshe Oren (Israel). DNA encoding
siRNA against MDM2 was described [40] and was from
Ruiwen Zhang (University of Alabama-Birmingham).
Cell culture and transfections
Saos-2 cells are a p53-null human osteosarcoma cell line.
MDM2/p53 double knockout (DKO) mouse embryo
fibroblasts were from Rudy Alarcon (Stanford University).
Cell lines were maintained at 37°C in Dulbeccos Modi-
fied Eagles Medium (DMEM) supplemented with 10%
fetal bovine serum and antibiotics (1% penicillin and
streptomycin). Transfections in Saos-2 or MDM2/p53
DKO cells were done using Fugene-6 transfection reagent
(Roche) according to the manufacturers protocol when
cells were approximately 60% confluent. Total DNA in
each transfection was equalized by addition of empty
plasmid. Dexamethasone (Dex) was purchased from
Sigma and was dissolved in ethanol at a concentration of
1 mM. Dex was added to cells at a final concentration of
100 nM to activate GR, and cells harvested 20–24 hrs
later. Where indicated, the proteasome inhibitor MG132
(Boston Biochem) was added to a final concentration of
30 µM and the cells incubated for an additional 6 hrs
before harvesting.
Immunoprecipitations and Immunoblotting
To harvest cell lysates for immunoblotting, cells were
rinsed with 2 ml PBS and then scraped into 500 µl lysis
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% NP40,
PMSF, leupeptin) and transferred to microfuge tubes. The
cells were then incubated on ice for 30 min with occa-
sional vortexing, and spun at 4°C, 14,000 rpm for 15 min
to remove cellular debris. For co-immunoprecipitations,
lysates were immunoprecipitated overnight with 200 ng
anti-GR polyclonal antibody (clone E-20, Santa Cruz Bio-
technology). GR immunoprecipitates were isolated on
protein A agarose beads as described previously [39]. For
immunoblotting, protein lysates or GR immunoprecipi-
tates were resolved by sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis (SDS-PAGE) and transferred to
PVDF membranes for immunoblotting. Antibodies used
in immunoblotting included anti-HA monoclonal anti-
body (HA.11, Covance), anti-Flag monoclonal antibody
Ab-5 (Sigma-Aldrich), anti-GR polyclonal antibodies (E-
20 and P-20, Santa Cruz Biotechnology), anti-MDM2
monoclonal antibody SMP-14 (Santa Cruz Biotechnol-
ogy).
Luciferase Assays
To monitor p53 and p73 transcriptional activity, Saos-2
cells were transfected with 100 ng of each luciferase
reporter DNA (pG13-luc, p21-luc, MDM2-luc) and 50 ng
DNA encoding Flag p53 wt or Flag p73β wt. In some cases,
GR DNA was included in the transfection (100, 250, 500,
or 1000 ng) and cells were treated with Dex (100 nM) for
16–20 hrs before harvesting. To monitor GR transcrip-
tional activity, cells were transfected overnight with 200
ng GR-luc DNA and 100 ng DNA encoding GR. Cells were
then treated with Dex (100 nM) for 20–24 hrs before har-Molecular Cancer 2006, 5:68 http://www.molecular-cancer.com/content/5/1/68
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vesting. In some cases, p53 wt or p73 wt, or the various
chimeric proteins were included in the transfection. PRL-
TK DNA (5 ng) was included in each transfection as a nor-
malization control. Luciferase activity was monitored
using the dual-luciferase reporter assay kit (Promega
Corp.), according to the manufacturers protocol. P53 and
p73 protein expression levels were compared in these luci-
ferase experiments by densitometric scanning of films
using Image-J software. This allowed comparison of GR-
luc activity under conditions of comparable p53 and p73
protein expression.
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